Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression?

Brain Research Bulletin

Volumn 81, Issue 6, 2010, Pages 585-589

  Réus, Gislaine Z ^a   Stringari, Roberto B ^a   Kirsch, Tamires R ^a   Fries, Gabriel R ^b   Kapczinski, Flávio ^b   Roesler, Rafael ^c   Quevedo, João ^a  

^a Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina   (Brazil)

^b Centro de Pesquisas   (Brazil)

^c Instituto Nacional de Ciência e Tecnologia Translacional Em Medicina   (Brazil)

Author keywords

Brain derived neurotrophic factor; Depression; Imipramine; Memantine; NMDA receptor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; IMIPRAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIMMING TEST; HIPPOCAMPUS; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; IMIPRAMINE; LOCOMOTION; MALE; MEMANTINE; MOTOR ACTIVITY; N-METHYLASPARTATE; NEUROPSYCHOLOGICAL TESTS; RATS; RATS, WISTAR; SWIMMING; TIME FACTORS;

EID: 77049122009     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.11.013     Document Type: Article

References (46)

1. Almeida R.C., Felisbino C.S., López M.G., Rodrigues A.L.S., and Gabilan N.H. Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav. Brain Res. 168 (2006) 318-322
2. Barbon A., Popoli M., La Via L., Moraschi S., Vallini I., Tardito D., Tiraboschi E., Musazzi L., Giambelli R., Gennarelli M., Racagni G., and Barlati S. Regulation of editing and expression of glutamate α-amino-propionic-acid (AMPA)/kainite receptors by antidepressant drugs. Biol. Psychiatry 59 (2006) 713-720
3. Berman R.B., Cappielo A., Anand A., Oren D.A., George R.H., Charney D.S., and Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47 (2000) 351-354
4. Bonanno G., Giambelli R., Raiteri L., Tiraboschi E., Zappettini S., Musazzi L., Raiteri M., Racagni G., and Popoli M. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 25 (2005) 3270-3279
5. Carvalho A.L., Caldeira M.V., Santos S.D., and Duarte C.B. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br. J. Pharmacol. 153 (2008) 310-324
6. Castrén E., Võikar V., and Rantamäki T. Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. 7 (2007) 18-21
7. Castrén E. Is mood chemistry?. Nat. Rev. Neurosci. 6 (2005) 241-246
8. De Foubert G., Carney S.L., Robinson C.S., Destexhe E.J., Tomlinson R., Hicks C.A., Murray T.K., Gaillard J.P., Deville C., Xhenseval V., Thomas C.E., O'Neill M.J., and Zetterström T.S. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128 (2004) 597-604
9. Drever B.D., Anderson W.G., Johnson H., O'Callaghan M., Seo S., Choi D.Y., Riedel G., and Platt B. Memantine acts as a cholinergic stimulant in the mouse hippocampus. J. Alzheimers Dis. 12 (2007) 319-333
10. Duman R.S., and Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59 (2006) 1116-1127
11. Ferguson J.M., and Shingleton R.N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin. Neuropharmacol. 30 (2007) 136-144
12. Feyissa A.M., Chandran A., Stockmeier C.A., and Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2008) 70-74
13. Frey B.N., Andreazza A.C., Ceresér K.M.M., Martins M.R., Valvassori S.S., Réus G.Z., Quevedo J., and Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 79 (2006) 281-286
14. Garcia L.B., Comim C.M., Valvassori S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., Stertz L., Fries G., Gavioli E., Kapczinski F., and Quevedo J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 140-144
15. Garcia L.B., Comim C.M., Valvassori S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., Stertz L., Fries G., Gavioli E., Kapczinski F., and Quevedo J. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin. Pharmacol. Toxicol. 103 (2008) 502-506
16. Itoh T., Tokumura M., and Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur. J. Pharmacol. 13 (2004) 135-142
17. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., and Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 15 (2002) 143-148
18. Kos T., Legutko B., Danysz W., Samoriski G., and Popik P. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-d-aspartate receptor antagonist neramexane in mice. J. Pharmacol. Exp. Ther. 318 (2006) 1128-1136
19. Kozisek M.E., Middlemas D., and Bylund D.B. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol. Ther. 117 (2008) 30-51
20. Krishnan V., and Nestler E.J. The molecular neurobiology of depression. Nature 455 (2008) 894-902
21. Lewin G.R., and Barde Y.A. Physiology of the neurotrophins. Annu. Rev. Neurosci. 19 (1997) 215-221
22. Liebrenz M., Borgeat A., Leisinger R., and Stobler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med. Wkly. 137 (2007) 234-236
23. Lipton S.A. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurological disorders. J. Alzheimer's Dis. 6 (2004) 61-74
24. Marini A.M., Popolo M., Pan H., Blondeau N., and Lipsky R.H. Brain adaptation to stressful stimuli: a new perspective on potential therapeutic approaches based on BDNF and NMDA receptors. CSN Neurol. Disord. Drug Targets 7 (2008) 382-390
25. Martinowich K., Manji H., and Lu B. New insights into BDNF function in depression and anxiety. Nature 10 (2007) 1089-1093
26. Marvanová M., Lakso M., Pirhonen J., Nawa N., Hiroyoki N., Wong G., and Castre E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkb receptor expression in rat brain. Mol. Cell. Neurosci. 18 (2001) 247-258
27. McArthur R., and Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol. Biochem. Behav. 84 (2006) 436-452
28. Moutsimilli L., Farley S., Dumas S., El Mestikawy S., Giros B., and Tzavara E.T. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49 (2005) 890-900
29. Muhonen L.H., Lönnqvist J., Lahti J., and Alho H. Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence. Psychiatry Res. 167 (2009) 115-122
30. Onogi H., Ishigaki S., Nakagawasai O., Arai-Kato Y., Arai Y., Watanabe H., Miyamoto A., Tan-no K., and Tadano T. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol. Pharm. Bull. 32 (2009) 850-855
31. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., and Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol. Psychiatry 15 (2008) 181-184
32. Porsolt R.D., Le Pichon M., and Jalfre M. Animal model of depression. Nature 266 (1977) 730-732
33. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., and Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28 (2008) 631-637
34. Rammes G., Danysz W., and Parsons C.G. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 6 (2008) 55-78
35. Réus G.Z., Valvassori S.S., Machado R.A., Martins M.R., Gavioli E.C., and Quevedo J. Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. Naunyn Schmiedeberg's Arch. Pharmacol. 376 (2008) 295-300
36. Roceri M., Hendriks W., Racagni G., Ellenbroek B.A., and Riva M.A. Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. Mol. Psychiatry 7 (2002) 609-616
37. Rogóz Z., Skuza G., and Legutko B. Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol. Rep. 60 (2008) 817-826
38. Rogóz Z., Skuza G., Maj J., and Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42 (2002) 1024-1030
39. Sanacora G., Zarate C.A., Krystal J.H., and Manji H.J. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature 7 (2008) 426-437
40. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., and Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (2002) 3251-3261
41. Siuciak J.A., Lewis D.R., Wiegand S.J., and Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56 (1997) 131-137
42. Skuza G., and Rogóz Z. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol. J. Pharmacol. 55 (2003) 1149-1152
43. Skuza G., and Rogóz Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J. Physiol. Pharmacol. 57 (2006) 217-229
44. Zarate C.A., and Manji H.K. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp. Neurol. 211 (2008) 7-10
45. Zarate C.A., Singh J.B., Carson P.J., Brutshe N.E., Ameli R., Luckenbaugh D.A., Charney D.S., and Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment resistant major depression. Arch. Gen. Psychiatry 63 (2006) 856-864
46. Zdanys K., and Tampi R.R. A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1362-1374